Author of

• 17398

  +

  P2.01 - Poster Session with Presenters Present (ID 461)

  • Event: WCLC 2016
  • Type: Poster Presenters Present
  • Track: Biology/Pathology
  • Presentations: 1
  • Moderators:
  • Coordinates: 12/06/2016, 14:30 - 15:45, Hall B (Poster Area)

  • 17451

    +

    P2.01-053 - PD-L1 Expression in Patients with Small Cell Lung Cancer (ID 4835)

    14:30 - 14:30  |  Author(s): L. Zhou
    • Abstract

    Background:
    Small Cell Lung Cancer (SCLC) is a highly aggressive tumor. Alough most of SCLC cases are sensitive to chemotherapy, the prognosis of SCLC is still dismal. Programmed death-ligand 1 (PD-L1), which is expressed on many cancer cells, has been reported as a predictive biomarker for immune checkpoint inhibitors treatment in advanced non-small-cell lung cancer. However, expression of PD-L1 in SCLC has not been fully studied.
    
    Methods:
    Totally 72 surgical specimens of SCLC ( 42 primary, 30 metastasis) were involved in this study. Only 5 cases had received neoadjuvant chemotherapy before surgery while 67 cases did not. Rabbit anti-PD-L1 monoclonal antibody (Spring Bio, SP142,1:100) was used on tissue microarray to detect the expression of PD-L1 on these cases.
    
    Results:
    PD-L1 was strongly expressed on the membrane of tumor cells of 8 cases (11.1%) and in the immune stroma of 35 cases (48.6%). Another 29 cases (40.3%) were totally negative for PD-L1 staining. Expression of PD-L1 was significantly associated with tumor sites (primary, P=0.017) and had a trend of low lymphonode metastasis(P=0.057). There was no significant correlation between PD-L1 expression and other clinical-pathological parameters (age, gender, T staging, nodal status, TNM staging, vascular invasion and treatment).
    
    Conclusion:
    PD-L1 was expressed in more than half of SCLC cases and correlated with tumor sites. These data may provide useful information for future research or clinical trial on immune checkpoint therapy for SCLC.